Clear Labs expands collaboration with Pillar Biosciences to automate oncoReveal(R) Myeloid v2 and Essential MPN panels on the Clear Dx(R) platform. Clear Labs, Inc. Nov 10, 2026, 13:00 ET Clear Labs extends its fully automated NGS workflows to hematologic malignancy research, helping laboratories bring myeloid and myeloproliferative neoplasm (MPN) profiling in-house with less hands-on time and greater consistency SAN CARLOS, Calif., Nov. 10, 2026 /PRNewswire-PRWeb/ - Clear Labs, a leader in fully automated next-generation sequencing (NGS) solutions, today announced an expanded collaboration with Pillar Biosciences to automate the research-use-only (RUO) oncoReveal(R) Myeloid v2 Panel and oncoReveal(R) Essential MPN Panel on the Clear Dx(R) platform. The collaboration provides turnkey automation for Pillar's kitted hematologic oncology panels in a simple, easy-to-use workflow on the Clear Dx platform, giving laboratories a standardized, streamlined path to in-house myeloid and MPN profiling. The announcement builds on Clear Labs' menu of automated workflows featuring Pillar's SLIMamp(R) chemistry and will mark Clear Labs' first application of its automation to hematologic malignancies, as the company continues to expand its offerings to provide labs with a comprehensive menu of assay panels for oncology research. Molecular profiling has become central to the classification, risk stratification, and monitoring of myeloid malignancies and MPNs. As recommended gene content grows and variant classes such as long FLT3 internal tandem duplications (ITDs) become more important to capture, laboratories face mounting pressure from manual, labor-intensive library preparation, limited skilled staff, and run-to-run variability. Many continue to rely on centralized send-out testing as a result, adding cost and turnaround time. "Bringing Pillar's hematologic oncology panels onto Clear Dx is a natural next step in extending our automation into oncology," said Dr. Ramin Khaksar, Co-founder, COO and CSO, Clear Labs. "Together, we are helping laboratories of all sizes bring advanced genomics in-house, reduce reliance on send-outs, and deliver consistent, high-quality results." "Hematology laboratories want to run comprehensive myeloid and MPN profiling in-house, but manual library prep remains a real barrier to scaling," said Daniel Harma, Chief Commercial Officer, Pillar Biosciences. "By pairing our oncoReveal Myeloid v2 and Essential MPN panels with the Clear Dx platform, we are giving laboratories the same simple SLIMamp chemistry they already trust, now with automation that reduces hands-on time and standardizes results from run to run." Two hematologic panels, one automated workflow oncoReveal(R) Myeloid v2 Panel and oncoReveal(R) Essential MPN Panel both use Pillar's proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp(R) technology, a tiled-amplicon, single-tube target enrichment chemistry well suited to automation. On the Clear Dx platform, key steps in library preparation and sequencing setup are automated, reducing manual pipetting and the potential for error while improving reproducibility across runs and operators. Key Clear Dx features and benefits for laboratories include: * Reduced hands-on time: automated library preparation and sequencing setup on Clear Dx reduces hands-on time significantly. * Walkaway operation: library preparation and sequencing setup run with minimal operator intervention, freeing skilled laboratory staff for analysis and other higher-value work. * Standardized, reproducible results: automation minimizes operator-to-operator and run-to-run variability, supporting consistent performance as testing volumes grow. * One platform for multiple oncology workflows: Clear Dx supports targeted solid tumor sequencing, liquid biopsy, and fusion detection workflows. Adding myeloid and MPN panels lets laboratories consolidate oncology NGS testing on a single automated system. * Integrated data analysis: sequencing data are analyzed with Pillar's PiVAT(R) software, supporting an efficient path from sample to result. * Flexible downstream data workflows: Clear Dx is designed to work with secondary and tertiary bioinformatics platforms for variant analysis, interpretation, and reporting. * Proven automation at scale: more than 100 Clear Labs systems are in use across leading laboratories today. Together, these capabilities let laboratories run myeloid and MPN research testing on the Clear Dx platform with Pillar's kitted reagents, keeping samples, data, and turnaround time under local control. Availability The automated oncoReveal Myeloid v2 and Essential MPN workflows on Clear Dx are expected to be available in early 2027. Laboratories interested in early access can contact Clear Labs at https://www.clearlabs.com/contact-2womenshealth/. The oncoReveal Myeloid v2 Panel, oncoReveal Essential MPN Panel, and Clear Dx platform are for research use only. Not for use in diagnostic procedures. About Clear Labs Clear Labs is a pioneer in fully automated next-generation sequencing (NGS) solutions spanning oncology and infectious disease applications. With a focus on simplicity, speed, and precision, Clear Labs empowers laboratories to bring advanced genomics in-house, reducing reliance on send-outs and enabling consistent, high-quality results. For more information, visit www.clearlabs.com. About Pillar Biosciences Pillar Biosciences is a global provider of next-generation sequencing (NGS) kitted solutions designed to deliver high analytical performance and operational efficiency for cancer testing. Powered by proprietary SLIMamp(R) and PiVAT(R) technologies, Pillar enables localized testing to expand access to complex molecular diagnostics worldwide. The company offers a growing portfolio of IVD and RUO NGS kits for tumor profiling, biomarker analysis, and molecular research and monitoring applications. For more information, visit pillarbiosci.com and connect with 2womenshealth on LinkedIn. Media Contact Brian Wright, Pillar Biosciences, Inc., 1 800-514-9307, [email protected], https://www.pillarbiosci.com/ SOURCE Clear Labs, Inc.

"Our goal is to bring high-confidence microbial identification into more laboratories by eliminating the technical and logistical barriers to sequencing." — Sasan Amini, CEO, Clear Labs